Follow
Usha Kandpal Bughani
Usha Kandpal Bughani
National Inst of Immunology, Ranbaxy Research labs, Emory Univ, Jubilant Biosys, Biocon
Verified email at jubilantbiosys.com
Title
Cited by
Cited by
Year
T cell ageing: effects of age on development, survival & function
N Salam, S Rane, R Das, M Faulkner, R Gund, U Kandpal, V Lewis, ...
Indian Journal of Medical Research 138 (5), 595-608, 2013
1672013
Inducible nitric oxide synthase in T cells regulates T cell death and immune memory
M Vig, S Srivastava, U Kandpal, H Sade, V Lewis, A Sarin, A George, ...
The Journal of clinical investigation 113 (12), 1734-1742, 2004
1402004
MK2: a novel molecular target for anti-inflammatory therapy
S Duraisamy, M Bajpai, U Bughani, SG Dastidar, A Ray, P Chopra
Expert opinion on therapeutic targets 12 (8), 921-936, 2008
872008
T cell activation and differentiation is modulated by a CD6 domain 1 antibody Itolizumab
U Bughani, A Saha, A Kuriakose, R Nair, RB Sadashivarao, ...
PloS one 12 (7), e0180088, 2017
512017
Molecular targeting of E3 ligases–a therapeutic approach for cancer
M Lakshmanan, U Bughani, S Duraisamy, M Diwan, S Dastidar, A Ray
Expert Opinion on Therapeutic Targets 12 (7), 855-870, 2008
332008
Pentoxifylline functions as an adjuvant in vivo to enhance T cell immune responses by inhibiting activation-induced death
R Suresh, M Vig, S Bhatia, EPB Goodspeed, B John, U Kandpal, ...
The Journal of Immunology 169 (8), 4262-4272, 2002
272002
Naive CD4 T cells from aged mice show enhanced death upon primary activation
H Mattoo, M Faulkner, U Kandpal, R Das, V Lewis, A George, S Rath, ...
International immunology 21 (11), 1277-1289, 2009
242009
Recent patents reveal microtubules as persistent promising target for novel drug development for cancers
U Bughani, S Li, HC Joshi
Recent patents on anti-infective drug discovery 4 (3), 164-182, 2009
152009
Chemoprevention of familial adenomatous polyposis by bromo‐noscapine (EM011) in the ApcMin/+ mouse model
S Li, AM Ghaleb, J He, U Bughani, AB Bialkowska, VW Yang, HC Joshi
International journal of cancer 131 (6), 1435-1444, 2012
122012
Noscapinoids: A new class of anticancer drugs demand biotechnological intervention
HC Joshi, A Salil, U Bughani, P Naik
Medicinal plant biotechnology, 303-320, 2010
102010
Enhanced soluble production of biologically active recombinant human p38 mitogen-activated-protein kinase (MAPK) in Escherichia coli
SK Khattar, P Gulati, PK Kundu, V Singh, U Bughani, M Bajpai, KS Saini
Protein and Peptide Letters 14 (8), 756-760, 2007
102007
LewisV
N Salam, S Rane, R Das, M Faulkner, R Gund, U Kandpal
Mattoo H., Prabhu S., Ranganathan V., Durdik J., George A., RathS., Bal V …, 2013
62013
Use of a CD6 binding partner and method based thereon
P Nair, R Melarkode, BS Manian, A Barve, U Bughani, JEM Casimiro
US Patent 10,189,899, 2019
42019
874 Development of BCA101, a bifunctional antibody capable of simultaneously disabling EGFR and TGFβ signaling, as novel single-agent immunotherapy
SR Boreddy, R Nair, A Banerjee, A Kuriakose, PK Pandey, C Dey, M Shri, ...
Journal for ImmunoTherapy of Cancer 9 (Suppl 2), 2021
32021
BCA101 is a tumor-targeted bifunctional fusion antibody that simultaneously inhibits EGFR and TGFβ signaling to durably suppress tumor growth
SR Boreddy, R Nair, PK Pandey, A Kuriakose, SB Marigowda, C Dey, ...
Cancer Research 83 (11), 1883-1904, 2023
22023
Use of itolizumab to reduce phosphorylation of cd6
P Nair, A Saha, RB Sadashivarao, U Bughani, R Melarkode
US Patent App. 16/387,442, 2019
22019
Immunotherapy methods using anti-PD-L1 antibodies in combination with EGFR1 targeted-TGF-beta immunomodulatory fusion proteins
N Govindappa, SP Srinivasa, U Bughani, N Reshmi
US Patent 11,060,097, 2021
12021
Use of a CD6 binding partner and method based thereon
P Nair, R Melarkode, BS Manian, A Barve, U Bughani, JEM Casimiro
US Patent 11,028,168, 2021
12021
Correction: T cell activation and differentiation is modulated by a CD6 domain 1 antibody Itolizumab
U Bughani, A Saha, A Kuriakose, R Nair, RB Sadashivarao, ...
Plos one 13 (1), e0192335, 2018
12018
Use of itolizumab to reduce phosphorylation of cd6
P Nair, A Saha, RB Sadashivarao, U Bughani, R Melarkode
US Patent App. 18/335,542, 2024
2024
The system can't perform the operation now. Try again later.
Articles 1–20